David Arkowitz
CIK 1296999 · Chief Financial Officer · last filed 2025-11-24
David Arkowitz is a Chief Financial Officer who has filed 72 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for IBIO, was dated Nov 24, 2025. Across all open-market trades the lifetime net is +$88.4K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $5.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$5.51M
10
72
$88.4K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IBIO | Director | 18,382 | $1.39 | $25.6K | $50.0K | 3 | 2025-11-24 |
| KINETA, INC./DE (KA) Delisted | Director | — | $0.57 | — | $0 | 2 | 2024-09-05 |
| MCRB | Chief Financial Officer | 9,122 | $4.80 | $43.8K | -$9.7K | 8 | 2024-02-16 |
| F-star Therapeutics, Inc. (FSTX) Delisted | Director | 0 | $7.12 | $0 | $0 | 3 | 2023-03-09 |
| KINETA, INC./DE (YMTX) Delisted | Director | 621 | $13.23 | $8.2K | $0 | 2 | 2021-06-04 |
| FLXN | Chief Financial Officer | 220,719 | $24.65 | $5.44M | $102.9K | 17 | 2021-05-12 |
| F-star Therapeutics, Inc. (SBPH) Delisted | Director | 9,482 | — | — | $30.6K | 12 | 2020-11-23 |
| KINETA, INC./DE (PTI) Delisted | Director | — | — | — | $0 | 2 | 2020-07-01 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | EVP, CFO and CBO | 1,806 | — | — | -$85.4K | 20 | 2011-06-01 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Chief Financial Officer | — | — | — | $0 | 1 | 2007-03-14 |
Recent Filings
72 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-11-24 | IBIO | Grant (A) | — | $0 | EDGAR |
| 2025-07-02 | — | Disp (D) | −16,571 | $0 | |
| 2025-06-25 | — | Mixed | +13,794 | $6.4K | |
| 2025-01-13 | IBIO | Buy (P) | +18,382 | $50.0K | EDGAR |
| 2024-11-25 | IBIO | Grant (A) | — | $0 | EDGAR |
| 2024-09-05 | KINETA, INC./DE (KA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-16 | MCRB | Mixed | +6,686 | -$4.3K | EDGAR |
| 2023-10-31 | MCRB | Mixed | +9,143 | -$5.5K | EDGAR |
| 2023-05-01 | MCRB | Grant (A) | +42,500 | $0 | EDGAR |
| 2023-04-14 | KINETA, INC./DE (KA) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.